How much does a single bottle of Enasidenib cost in RMB?

Enasidenib is a targeted drug mainly used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) gene mutations. IDH2 mutation accounts for a certain proportion of AML patients. It causes the accumulation of 2-hydroxyglutarate (2-HG) in tumor cells, hinders the differentiation and maturation of leukemia cells, and thus promotes the progression of the disease. Ensidipine selectively inhibits the activity of IDH2 mutant enzyme, reduces 2-HG levels, restores the differentiation ability of leukemia cells, and gradually transforms immature leukemia cells into mature blood cells, thereby controlling the development of the disease.

Its unique molecular targeting effect makes it different from traditional chemotherapy drugs. It has relatively low toxicity to normal cells. It can be used as a single drug treatment or in combination with low-intensity chemotherapy or other targeted drugs in clinical practice to improve the efficacy.

In terms of price, since Encidipine generic medicine has not yet been launched in China, patients can only obtain it through overseas channels. Common specifications include 50 mg 30 tablets and 100 mg 30 tablets. The price per box may be as high as more than 300,000 yuan, and the price will be greatly affected by exchange rate fluctuations. In order to reduce the cost of treatment, generic versions of drugs have appeared in some overseas markets. For example, the 50mg*30 tablet version produced in Laos costs only about 1,000 yuan. At the same time, its main active ingredients remain the same as the original drug, providing patients with a more economical and accessible choice. However, when purchasing overseas drugs, patients need to pay attention to the formal sources of drugs to ensure quality and efficacy and avoid safety issues caused by informal channels.

In general, ensidipine provides a precise targeted treatment option for IDH2 mutation-positive AML patients, especially for relapsed or refractory patients. Genetic testing is required before use to confirm IDH2 mutation positivity. At the same time, a safe, effective, and accessible treatment plan should be selected based on the doctor's evaluation and economic conditions.

Reference materials:https://www.idhifa.com/